The less-known face of dupilumab: its role in mesenchymal stem cells by interleukin-13 modulation

Br J Dermatol. 2021 Jul;185(1):217-219. doi: 10.1111/bjd.19892. Epub 2021 Apr 26.

Authors

A Campanati¹, M Di Vincenzo², G Radi¹, G Rizzetto¹, G Carnevale³, S Marchi², M Orciani², A Offidani¹

Affiliations

¹ Dermatological Clinic, Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy.
² Department of Clinical and Molecular Sciences - Histology, Università Politecnica delle Marche, Ancona, Italy.
³ Department of Surgery, Medicine, Dentistry and Morphological Sciences with Interest in Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy.

PMID: 33657639
DOI: 10.1111/bjd.19892

No abstract available

Publication types

Letter

MeSH terms

Anti-Asthmatic Agents*
Antibodies, Monoclonal, Humanized
Interleukin-13
Mesenchymal Stem Cells*

Substances

Anti-Asthmatic Agents
Antibodies, Monoclonal, Humanized
Interleukin-13
dupilumab